NCT00151060View on ClinicalTrials.gov

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 1998

Primary Completion Date

November 30, 2004

Study Completion Date

June 30, 2006

Conditions
Prostate Cancer
Interventions
DRUG

Estramustine

DRUG

Etoposide

DRUG

Paclitaxel

Trial Locations (1)

Unknown

The University of Michigan Comprehensive Cancer, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00151060 - Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate | Biotech Hunter | Biotech Hunter